Related Experiment Video
Updated: Mar 22, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Rapamycin causes growth arrest and inhibition of invasion in human chondrosarcoma cells
Jian Song1, Xiaobo Wang, Jiaxue Zhu
1Department of Orthopaedics, Shandong Jining No.1 People's Hospital, Jining, Shandong, 272000, China.
Purpose:
Chondrosarcoma is a highly malignant tumor that is characterized by a potent capacity to invade locally and cause distant metastasis and notable for its lack of response to conventional chemotherapy or radiotherapy. Rapamycin, the inhibitor of mammalian target of rapamycin (mTOR), is a valuable drug with diverse clinical applications and regulates many cellular processes. However, the effects of rapamycin on cell growth and invasion of human chondrosarcoma cells are not well known.
Methods:
We determined the effect of rapamycin on cell proliferation, cell cycle arrest and invasion by using MTS, flow cytometry and invasion assays in two human chondrosarcoma cell lines, SW1353 and JJ012. Cell cycle regulatory and invasion-related genes' expression analysis was performed by quantitative RT-PCR (qRT-PCR). We also evaluated the effect of rapamycin on tumor growth by using mice xenograph models.
Results:
Rapamycin significantly inhibited the cell proliferation, induced cell cycle arrest and decreased the invasion ability of human chondrosarcoma cells. Meanwhile, rapamycin modulated the cell cycle regulatory and invasion-related genes' expression. Furthermore, the tumor growth of mice xenograph models with human chondrosarcoma cells was significantly inhibited by rapamycin.
Conclusions:
These results provided further insight into the role of rapamycin in chondrosarcoma. Therefore, rapamycin targeted therapy may be a potential treatment strategy for chondrosarcoma.
Insights
Rapamycin effectively inhibits chondrosarcoma cell growth and invasion. This mTOR inhibitor shows promise as a targeted therapy for chondrosarcoma, reducing tumor growth in preclinical models.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Chondrosarcoma is a malignant bone tumor resistant to conventional treatments.
- Rapamycin (mTOR inhibitor) has diverse cellular effects but its role in chondrosarcoma is unclear.
Purpose of the Study:
- To investigate the effects of rapamycin on human chondrosarcoma cell proliferation, cell cycle, and invasion.
- To evaluate rapamycin's efficacy in a preclinical chondrosarcoma xenograph model.
Main Methods:
- MTS assays, flow cytometry, and invasion assays were used on SW1353 and JJ012 cell lines.
- Quantitative RT-PCR analyzed gene expression related to cell cycle and invasion.
- Mice xenograft models assessed in vivo tumor growth inhibition.
Main Results:
- Rapamycin significantly reduced chondrosarcoma cell proliferation and invasion.
- Cell cycle arrest was induced by rapamycin.
- Rapamycin treatment led to significant inhibition of tumor growth in vivo.
Conclusions:
- Rapamycin demonstrates potent anti-cancer effects against human chondrosarcoma cells.
- Targeted therapy with rapamycin presents a potential therapeutic strategy for chondrosarcoma.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
PI3K/mTOR/AKT Signaling Pathway
Abnormal Proliferation
Negative Regulator Molecules
Inhibition of Cdk Activity

